An umbrella trial of 25 targeted treatments in all cancer types tackles treatment selection on the basis of genetic events rather than by tumour histology.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeted therapy for hepatocellular carcinoma
Signal Transduction and Targeted Therapy Open Access 11 August 2020
-
Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma
BMC Cancer Open Access 23 June 2020
-
Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
BMC Cancer Open Access 15 April 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. NCI-MATCH trial pushes cancer umbrella trial paradigm. Nat Rev Drug Discov 14, 513–515 (2015). https://doi.org/10.1038/nrd4694
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4694
This article is cited by
-
Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma
BMC Cancer (2020)
-
Targeted therapy for hepatocellular carcinoma
Signal Transduction and Targeted Therapy (2020)
-
Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes
Communications Biology (2020)
-
Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
BMC Cancer (2020)
-
Clinical utility of custom-designed NGS panel testing in pediatric tumors
Genome Medicine (2019)
